Anavex Life Sciences Corp. (AVXL)
Automate Your Wheel Strategy on AVXL
With Tiblio's Option Bot, you can configure your own wheel strategy including AVXL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AVXL
- Rev/Share 0.0
- Book/Share 1.1726
- PB 7.9311
- Debt/Equity 0.0
- CurrentRatio 14.7931
- ROIC -0.3887
- MktCap 793957740.0
- FreeCF/Share -0.3504
- PFCF -26.6304
- PE -22.011
- Debt/Assets 0.0
- DivYield 0
- ROE -0.3121
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Does Anavex's Alzheimer's Drug Actually Confer Benefit?
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Anavex Life Sciences' OLE study demonstrates that its Alzheimer's drug works for years beyond the clinical study. The OLE expands efficacy to include patients' behavioral abilities. The Anavex drug may offer years of extra mental lucidity and greater self-sufficiency among Alzheimer's patients. The EU's approval of Blarcamesine could increase Anavex's market value from $800 million to $8 billion.
Read More
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Positive
Blarcamesine shows limited effectiveness against mild Alzheimer's disease, but not against moderate Alzheimer's. However, it does appear effective when started early. These result could lead to European Medicines Agency approval. The benefits of blarcamesine may increase over time due to reduced oxidative stress, though side effects like diziness and confusion may occur. Given the lack of effective Alzheimer's treatments, I cautiously recommend buying Anavex stock based on these promising results.
Read More
Anavex Life Sciences Corp. (AVXL) Q2 2025 Earnings Call Transcript
Published: May 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q2 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Clint Tomlinson - Investor Relations Christopher Missling - President & Chief Executive Officer Sandra Boenisch - Principal Financial Officer Conference Call Participants Soumit Roy - Jones Research Tom Bishop - BI Research Clint Tomlinson Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 Second Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call.
Read More
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET Webcast and Conference Call To be Held Tuesday, May 13, 2025, 8:30 am ET
Read More
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Study ANAVEX3-71-SZ-001 successfully completes enrollment with a total of 71 participants Both Part A (16 participants) and Part B (55 participants) of the placebo-controlled Phase 2 study fully enrolled Top line data expected in the second half of 2025 NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced the successful completion of enrollment in its Phase 2 clinical study …
Read More
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from May 7 – 8, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:30 PM (ET) on Wednesday, May 7th, 2025.
Read More
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board gave an oral presentation titled, “Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial” at the 9th International Conference on Alzheimer's Disease …
Read More
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Published: February 14, 2025 by: Seeking Alpha
Sentiment: Positive
Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses.
Read More
Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Anavex Life Sciences Corp. expects feedback from the European Medicines Agency on blarcamesine for the treatment of patients with Alzheimer's Disease by year-end of 2025. The global market for Alzheimer's Disease is estimated to reach $15.5 billion by 2031. AVXL has top-line data from the ongoing phase 2 study, using blarcamesine for the treatment of patients with Schizophrenia, expected to be released in 2025.
Read More
Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Anavex Life Sciences Corp. (NASDAQ:AVXL ) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Clint Tomlinson - IR Christopher Missling - President & CEO Sandra Boenisch - Principal Financial Officer Conference Call Participants Tom Bishop - BI Research Clint Tomlinson Good morning, everyone, and welcome to the Anavex Life Sciences Fiscal 2025 First Quarter Conference Call. My name is Clint Tomlinson, and I will be your host for today's call.
Read More
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Company to host a webcast t oday at 8:30 a.m. Eastern Time
Read More
About Anavex Life Sciences Corp. (AVXL)
- IPO Date 2006-08-02
- Website https://www.anavex.com
- Industry Biotechnology
- CEO Dr. Christopher U. Missling M.B.A., M.S., Ph.D.
- Employees 42